Compass Pathways is conducting a rolling submission to the FDA for COMP360, its psilocybin-based candidate for treatment-resistant depression.

From the articleHow J&J paved the way for Compass’ coming psychedelic drug launchAlso in Deep dive: Psychedelics back on FDA’s doorstep